TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9187164

Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizer (UN)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Jet nebulizer (JN)
Number of subjects: 113
Study: 1526089

Group type: EXPERIMENTAL
Intervention: 150 mg nizatidine twice daily
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine at bedtime
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Nizatidine (both doses)
Number of subjects: 456
Study: 3094360

Group type: EXPERIMENTAL
Intervention: Olive oil diet
Number of subjects: 23

Group type: COMPARATOR
Intervention: Corn oil diet
Number of subjects: 23
Study: 29750261

Group type: EXPERIMENTAL
Intervention: Sequential intensity-modulated radiation therapy
Number of subjects: 178
Study: 27912947

Group type: EXPERIMENTAL
Intervention: Qigong/Tai Chi Easy (QG/TCE)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sham Qigong (SQG)
Number of subjects: 87
Study: 24906029

Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg/day, titrated to 30 mg/day and 60 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 22502793

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) injections plus physical therapy (PT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Physical therapy (PT) alone
Number of subjects: 70
Study: 20412150

Group type: EXPERIMENTAL
Intervention: Mild sedation with midazolam (score of 3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Deep sedation with midazolam (score of 1)
Number of subjects: 12
Study: 18614875

Group type: EXPERIMENTAL
Intervention: Low serum alpha-fetoprotein level (<5.0 ng/ml)
Number of subjects: 383
Study: 15631865

Group type: EXPERIMENTAL
Intervention: GnRH-a plus tibolone
Number of subjects: 70

Group type: COMPARATOR
Intervention: GnRH-a alone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 70
Study: 11823400

Group type: EXPERIMENTAL
Intervention: Caudal anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: No caudal anesthesia (Control)
Number of subjects: 50
Study: 9878016

Group type: EXPERIMENTAL
Intervention: Recombinant gp160 immunization every 2 months for 5 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo every 2 months for 5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant gp160 immunization
Number of subjects: 0
Study: 7719750

Group type: EXPERIMENTAL
Intervention: Lavender oil (6 drops added to bath water daily for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no lavender oil)
Number of subjects: 0
Study: 2189075

Group type: EXPERIMENTAL
Intervention: Enalapril, 10-20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Captopril, 50-100 mg
Number of subjects: 12
Study: 6988034

Group type: EXPERIMENTAL
Intervention: Midline incision
Number of subjects: 579

Group type: COMPARATOR
Intervention: Transverse/oblique muscle-cutting incision
Number of subjects: 579
Study: 27324141

Group type: EXPERIMENTAL
Intervention: Flatbreads with 6 g GG, 4 g KM, and 15 g CPF plus 2 or 4 g GG
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control commercial high-fibre flatbread flour mix (atta)
Number of subjects: 38
Study: 26206423

Group type: EXPERIMENTAL
Intervention: Green tea extract (843.0 +/- 44.0 mg/day epigallocatechin gallate)
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 1075
Study: 23590801

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide pulses plus corticosteroids (6 or 12 pulses)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Corticosteroids alone (for FFS = 0)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Corticosteroids (with immunosuppressant adjunct when corticosteroids failed)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Age ≥65 years
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Anti-myeloperoxidase antibodies
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Eosinophils >3000/mm(3)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Sequelae
Number of subjects: 118
Study: 21837291

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA) in neutral position (P2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA) in 50% advanced position (P4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA) in both positions
Number of subjects: 12
Study: 19121573

Group type: EXPERIMENTAL
Intervention: guaifenesin 600 mg (G)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: benzonatate 200 mg (B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: combination of benzonatate 200 mg and guaifenesin 600 mg (B+G)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo (P)
Number of subjects: 30
Study: 16912719

Group type: EXPERIMENTAL
Intervention: Simplified head injury advice sheet
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard head injury advice sheet
Number of subjects: 200
Study: 15025743

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water
Number of subjects: 20
Study: 11124783

Group type: EXPERIMENTAL
Intervention: Ventilation tubes
Number of subjects: 187

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 187
Study: 9540874

Group type: EXPERIMENTAL
Intervention: Natural somatostatin (single bolus injection)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 8126502

Group type: EXPERIMENTAL
Intervention: 200 mg entacapone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg levodopa/50 mg carbidopa with 200 mg entacapone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg levodopa/50 mg carbidopa with 800 mg entacapone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2563190

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 67
Study: 1092513

Group type: EXPERIMENTAL
Intervention: Deanol (500 mg daily)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg daily)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 31163986

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study: 27652589

Group type: COMPARATOR
Intervention: Prasugrel 20 mg single dose
Number of subjects: 43

Group type: COMPARATOR
Intervention: Prasugrel 30 mg single dose
Number of subjects: 43

Group type: COMPARATOR
Intervention: Prasugrel 20 mg loading dose followed by 5 mg/day maintenance dose
Number of subjects: 43

Group type: COMPARATOR
Intervention: Prasugrel 30 mg loading dose followed by 7.5 mg/day maintenance dose
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 43
Study: 26598472

Group type: EXPERIMENTAL
Intervention: High-quality foster care intervention (n = 68)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Care-as-usual group (n = 68)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: High-quality foster care intervention
Number of subjects: 95
Study: 24019134

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC) ablation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Endoscopic surveillance
Number of subjects: 129
Study: 21615670

Group type: EXPERIMENTAL
Intervention: Exenatide 10 µg (subcutaneous) twice daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg (oral) daily
Number of subjects: 86
Study: 19427432

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 8351

Group type: COMPARATOR
Intervention: Simvastatin 20 to 40 mg/day
Number of subjects: 8351
Study: 16951474

Group type: EXPERIMENTAL
Intervention: External hip protectors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisphosphonates
Number of subjects: 0
Study: 15278032

Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal approach (TAPP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Open mesh herniorrhaphy
Number of subjects: 121
Study: 11753059

Group type: EXPERIMENTAL
Intervention: Repetitive dorsiflexion exercise to the point of typical symptoms (CAECS subjects)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Repetitive dorsiflexion exercise to the point of fatigue (control subjects)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline and postexercise comparison of vibratory sensation
Number of subjects: 20
Study: 9412550

Group type: COMPARATOR
Intervention: Budesonide (BUD) 800 micrograms/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Budesonide (BUD) 1,600 micrograms/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Budesonide (BUD) 3,200 micrograms/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 750 micrograms/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 1,500 micrograms/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 2,000 micrograms/d
Number of subjects: 28
Study: 7907097

Group type: EXPERIMENTAL
Intervention: ipsapirone (10.0 to 30.0 mg daily)
Number of subjects: 317

Group type: COMPARATOR
Intervention: lorazepam (2.0 to 6.0 mg daily)
Number of subjects: 317

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 317
Study: 2959901

Group type: EXPERIMENTAL
Intervention: Fenoterol (FNT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31399793

Group type: EXPERIMENTAL
Intervention: Universal ART offer
Number of subjects: 100
Study: 28478185

Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension (80cc plus 1.3% liposomal bupivacaine 20cc; total injection 100cc)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ropivacaine (periarticular injection of ropivacaine, ketorolac, morphine, and epinephrine in saline; 100cc)
Number of subjects: 96
Study: 24594853

Group type: EXPERIMENTAL
Intervention: Physical Training Program (PTP) for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physical Training Program (PTP) for 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline to 6 weeks delta
Number of subjects: 20
Study: 23512759

Group type: EXPERIMENTAL
Intervention: Trophic feeding
Number of subjects: 525

Group type: COMPARATOR
Intervention: Full feeding
Number of subjects: 525
Study: 21696635

Group type: EXPERIMENTAL
Intervention: EPA‐rich fish oil supplement (1060 mg EPA plus 274 mg DHA)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: DHA‐rich fish oil supplement (900 mg DHA plus 180 mg EPA)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 19728632

Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomies (BSSO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mandibular distraction osteogenesis (MDO)
Number of subjects: 0
Study: 16805356

Group type: EXPERIMENTAL
Intervention: Porter/Brown nasal hood
Number of subjects: 30

Group type: COMPARATOR
Intervention: Accutron nasal hood
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Porter/Brown nasal hood with reduced suction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Accutron nasal hood with reduced suction
Number of subjects: 30
Study: 12504644

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 10923757

Group type: EXPERIMENTAL
Intervention: Midazolam (0.075 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9275372

Group type: EXPERIMENTAL
Intervention: Extended parietal cell vagotomy (EPCV)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Subtotal gastrectomy (SG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EPCV
Number of subjects: 36

Group type: COMPARATOR
Intervention: SG
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EPCV and SG
Number of subjects: 36
Study: 1675650

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine detergent solution (Group A)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo detergent (Group B)
Number of subjects: 115
Study: 7093110

Group type: EXPERIMENTAL
Intervention: 600 mg aspirin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1200 mg aspirin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30552505

Group type: EXPERIMENTAL
Intervention: 6.4 g day−1 of sustained-release beta-alanine (CarnoSyn™, NAI, USA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 25
Study: 31089253

Group type: EXPERIMENTAL
Intervention: Sesame oil enriched with vitamin E (30 ml/day and 400 mg/day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sesame oil (30 ml/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sunflower oil (30 ml/day)
Number of subjects: 75
Study: 30359215

Group type: EXPERIMENTAL
Intervention: Comprehensive preventive counseling with focus on diet modification followed by remote counseling by phone every two weeks for 3 months (total of 6 sessions).
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care in Health centers including basic preventive counseling.
Number of subjects: 100
Study: 27865620

Group type: EXPERIMENTAL
Intervention: Chokeberry juice (300 mL/d)
Number of subjects: 38
Study: 24518194

Group type: EXPERIMENTAL
Intervention: Home-based exercise training in combination with conventional management (EX, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional management alone (CON, n = 20)
Number of subjects: 40
Study: 22206079

Group type: EXPERIMENTAL
Intervention: Tri-retinol 1.1% cream
Number of subjects: 34

Group type: COMPARATOR
Intervention: Tretinoin 0.025% cream
Number of subjects: 34
Study: 20565456

Group type: EXPERIMENTAL
Intervention: 150 mg i.v. administration of CAT-354
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 150 mg s.c. administration of CAT-354
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 300 mg s.c. administration of CAT-354 (two 150 mg injections)
Number of subjects: 30
Study: 17634488

Group type: EXPERIMENTAL
Intervention: 18FDG PET scan
Number of subjects: 116

Group type: COMPARATOR
Intervention: Surveillance program for PET-negative patients
Number of subjects: 116
Study: 11235707

Group type: EXPERIMENTAL
Intervention: CABG with cardiopulmonary bypass (CPB)
Number of subjects: 22

Group type: COMPARATOR
Intervention: CABG without cardiopulmonary bypass (CPB)
Number of subjects: 22
Study: 9279180

Group type: EXPERIMENTAL
Intervention: Nebulised frusemide (1 mg/kg/body weight)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intravenous frusemide (1 mg/kg/body weight)
Number of subjects: 19
Study: 8316580

Group type: EXPERIMENTAL
Intervention: Passive hip extension stretching
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Trunk flexor exercises
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hip extension stretching or trunk flexor exercises
Number of subjects: 25
Study: 2423806

Group type: EXPERIMENTAL
Intervention: Indoramin (50 mg t.i.d. per os)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 20
Study: 31603262

Group type: EXPERIMENTAL
Intervention: Interval sprinting exercise (ISE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 28904068

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study: 27170524

Group type: EXPERIMENTAL
Intervention: McKenzie method
Number of subjects: 70

Group type: COMPARATOR
Intervention: Motor control exercises
Number of subjects: 70
Study: 25801698

Group type: EXPERIMENTAL
Intervention: Eltrombopag treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 117
Study: 23073712

Group type: EXPERIMENTAL
Intervention: Daily home-based exercise programme and self-care (n=11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Self-care measures alone (n=12)
Number of subjects: 23
Study: 20813044

Group type: EXPERIMENTAL
Intervention: Story-based intervention for health communication
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Revised stories based on participant feedback
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Focus group evaluation of story booklets
Number of subjects: 10
Study: 18204344

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Current treatment (Control)
Number of subjects: 22
Study: 16600940

Group type: EXPERIMENTAL
Intervention: Yogurt-plus-quadruple therapy (AB-yogurt 400 mL/d for 4 weeks + quadruple therapy for 1 week)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Quadruple therapy only (without AB-yogurt)
Number of subjects: 138
Study: 14967868

Group type: EXPERIMENTAL
Intervention: 75 g CHO as a glucose solution at 15 min before exercise (‐15 trial)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 75 g CHO as a glucose solution at 75 min before exercise (‐75 trial)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 25 g CHO as a glucose solution 45 min before exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: 200 g CHO as a glucose solution 45 min before exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo 45 min before exercise
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pre-exercise CHO ingestion (any amount)
Number of subjects: 18
Study: 10977787

Group type: EXPERIMENTAL
Intervention: 1alphaD(2)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 8770990

Group type: EXPERIMENTAL
Intervention: 15 mg/day dose of anti-LFA1 monoclonal antibody (MoAb) with a loading dose of 30 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Additional group receiving the same protocol (15 mg/day with a loading dose of 30 mg)
Number of subjects: 15
Study: 1282180

Group type: EXPERIMENTAL
Intervention: Nicorandil 20 mg b.i.d. for 4 weeks
Number of subjects: 129

Group type: COMPARATOR
Intervention: Isosorbide-5-mononitrate (MN) 20 mg b.i.d. for 4 weeks
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg t.i.d. for 2 weeks then 20 mg t.i.d. for 4 weeks
Number of subjects: 129

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) 10 mg t.i.d. for 2 weeks then 20 mg t.i.d. for 4 weeks
Number of subjects: 129
Study: 30451891

Group type: EXPERIMENTAL
Intervention: Stannous fluoride products
Number of subjects: 54
Study: 27192639

Group type: EXPERIMENTAL
Intervention: Simultaneous third molar extraction during orthognathic surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prior extraction of third molars before orthognathic surgery
Number of subjects: 100
Study: 24982490

Group type: EXPERIMENTAL
Intervention: Smartphone application
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no smartphone application)
Number of subjects: 90
Study: 22393101

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 732
Study: 21097734

Group type: EXPERIMENTAL
Intervention: FOYC plus one of two brief parent interventions
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Control condition 'Wondrous Wetlands' plus a brief parent intervention
Number of subjects: 1360
Study: 19004914

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (ON-Q group)
Number of subjects: 168

Group type: COMPARATOR
Intervention: 0.9% NaCl (control group)
Number of subjects: 168
Study: 16487032

Group type: EXPERIMENTAL
Intervention: IFN alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: IFN in combination with amantadine or ribavirin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 22
Study: 14761489

Group type: EXPERIMENTAL
Intervention: Blood transfusion and scopolamine injection in addition to traditional therapy (gastrolavage, purgation, redox agent)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Traditional combined therapy (gastrolavage, purgation, redox agent)
Number of subjects: 400
Study: 10921566

Group type: EXPERIMENTAL
Intervention: Nutritional support with 15% fat and 50% fish oil (Group III)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nutritional support with 15% fat (Group II)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nutritional support with 35% fat (Group I, control)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 23
Study: 8970901

Group type: EXPERIMENTAL
Intervention: Free and total Pyr and Dpyr in serum
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Free serum levels of Pyr and Dpyr
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Renal clearance of free cross-link fraction
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fractional clearance of free fraction
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fractional clearance of conjugated fraction
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fractional excretion of free Dpyr
Number of subjects: 38
Study: 1452618

Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatographic method with o-phthaldialdehyde precolumn derivatization
Number of subjects: 0
Study: 6697676

Group type: EXPERIMENTAL
Intervention: Cefazolin 20 mg/kg i.v. administered with anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cefazolin 20 mg/kg i.v. administered 'on call'
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefoxitin 30 mg/kg i.v. administered with anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cefoxitin 30 mg/kg i.v. administered 'on call'
Number of subjects: 40
Study: 31713391

Group type: EXPERIMENTAL
Intervention: Laboratory technicians' reading ability evaluation
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Evaluation of coating, dyeing and clean quality of blood slides
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Evaluation of mixed infections reading ability
Number of subjects: 869

Group type: COMPARATOR
Intervention: Comparison of reading abilities among different hospital types
Number of subjects: 869

Group type: COMPARATOR
Intervention: Comparison of reading abilities among different administrative levels
Number of subjects: 869